|Videos|August 14, 2020

CV Risk Stratification Decision Factors

A discussion on which factors to consider when assessing the need for management/reduction of cardiovascular risk.

Episodes in this series

EP. 1 New Approaches in Targeting Triglycerides for the Reduction of Cardiovascular Risks

EP. 2 CV Health: Risk Prevention, Challenges, Education

Now Playing

EP. 3 CV Risk Stratification Decision Factors

EP. 4 The Potential CV Impact of Triglyceride Level Reduction

EP. 5 REDUCE-IT Trial Data Updates: Key Takeaways

Stay informed with the Medical Economics eNewsletter, delivering expert insights, financial strategies, practice management tips, and technology trends tailored for today’s physicians.

Latest CME

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

CV Risk Stratification Decision Factors

Episodes in this series

EP. 1 New Approaches in Targeting Triglycerides for the Reduction of Cardiovascular Risks

EP. 2 CV Health: Risk Prevention, Challenges, Education

EP. 3 CV Risk Stratification Decision Factors

EP. 4 The Potential CV Impact of Triglyceride Level Reduction

EP. 5 REDUCE-IT Trial Data Updates: Key Takeaways

Related Content

Socioeconomic status during early pregnancy could predict cardiovascular health later in life

DASH diet reduces heart attack risk in short and long term

REDUCE-IT Trial Data Updates: Key Takeaways

The Potential CV Impact of Triglyceride Level Reduction

CV Health: Risk Prevention, Challenges, Education

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Medical Economics

455 defendants charged in massive $6.5 billion health care fraud takedown

Inside the 10 worst health care fraud cases of 2026 so far

FDA-cleared AI tool flags hidden heart disease from a standard ECG

Charge less, earn more: A family doctor's case for direct primary care

Treating obesity as a disease: Will new Medicare, Medicaid programs expand access to GLP-1 drugs?